Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride

Eli Lilly is spending $3.25 billion to acquire Kelonia Therapeutics, a small biotech company developing cell therapies for cancer and autoimmune diseases, the companies announced Monday. Lilly could pay more if Kelonia achieves specified clinical, regulatory, and commercial milestones. The…